Mylan Says It Wins Motion To Enjoin GSK From Providing Paroxetine CR To Apotex

(RTTNews) - Mylan Inc. (MYL) Thursday said the U.S. District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK.L, GSK)in relation to Paroxetine CR, the generic version of GSK's Paxil CR.

GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic.

Mylan had previously been awarded damages of $106.7 million by the District Court after a favorable jury verdict in March.

In addition, the District Court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since September 30, 2013 as a result of GSK's ongoing breach. All of GSK's post-trial motions were denied.

Mylan said it is the only company to have successfully developed an FDA-approved generic version of this product.